Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF XTEN
Set alert
43.95 USD +0.21 +0.49%
As of Nov 2, 1:22 PM ET
43.81 Day range 43.99
41.84 52-week range 47.49
- YTD
- -4.91%
- 1 year
- -6.31%
- Open
- 43.88
- Prev close
- 43.74
- Mkt cap
- 1.04B
- Vol
- 157.22K
- Avg vol
- 324.46K
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 43.81
- High
- 43.99
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 43.37
- 200-d avg
- 45.04
- 1y target
- 0.00
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 43.37
- 200-day average
- 45.04
Analyst view
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
About Bondbloxx Bloomberg Ten Year Target Duration US Treasury ETF
Under normal circumstances, the fund will invest at least 80% of its net assets (plus the amount of any borrowings for investment purposes) in a portfolio of U.S. Treasury securities that collectively have an average duration of approximately 10 years, either directly or indirectly (e.g., through derivatives). The index is comprised of certain U.S. Treasury notes and bonds that are included in the Bloomberg U.S. Treasury Index. It is non-diversified.
News
- BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Stake Reduced by DUTCH ASSET Corp
- BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF (NYSEARCA:XTEN) Stock Short Interest Report for September
- 15,395 Shares in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN Bought by Sax Wealth Advisors LLC
- Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors
- Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer
- Why Investors Are Eyeing Short & Long U.S. Treasury ETFs
- Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
- Park Avenue Securities LLC Sells 37,510 Shares of BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
- Vir Biotechnology Reports Positive Updated Phase 1 Results for PSMA-targeting, PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
- Heck Capital Advisors LLC Has $9.10 Million Stock Holdings in BondBloxx Bloomberg Ten Year Target Duration US Treasury ETF $XTEN
Your note
Sign in to keep a note on XTEN — it syncs with the Stock Master app.